SHENYANG, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced its planned participation in the following investor conferences: Sep 9-10, 2010 Susquehanna Fourth Annual Beijing Management Summit Beijing Sep 13-14, 2010 Morgan Stanley Global Healthcare Conference NYC Oct 20-22, 2010 Citigroup Greater China Investor Conference Macau Nov 1-2, 2010 Goldman Sachs China Investment Frontier Conference Beijing Nov 3-5, 2010 Bank of America Merrill Lynch China Investment Summit Beijing Nov 9-11, 2010 Morgan Stanley Asia Pacific Summit 2010 Singapore
Please see http://bbs.3sbio.com/en/News/xShowInfo_nnn6.aspx?ID=65 for further updates.
About 3SBio Inc.
3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 500 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see http://www.3SBio.com for more information.
For more information, please contact: Investor Contacts Bo Tan Chief Financial Officer 3SBio Inc. Tel: +86-24-2581-1820 Email: [email protected] Tom Folinsbee Director of Investor Relations 3SBio Inc. Tel: +852-8191-6991 Email: [email protected]
SOURCE 3SBio Inc.
Share this article